NASDAQ:TOCATocagen Stock Price, Forecast & News

Tocagen's stock was trading at $1.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TOCA shares have decreased by 3.2% and is now trading at $1.50. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Tocagen.

Tocagen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tocagen.

Tocagen Inc (NASDAQ:TOCA) announced its quarterly earnings data on Thursday, April, 23rd. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.01. Tocagen had a negative net margin of 176,433.34% and a negative return on equity of 327.74%. View Tocagen's earnings history.

7 brokers have issued twelve-month price objectives for Tocagen's stock. Their forecasts range from $1.00 to $3.32. On average, they anticipate Tocagen's share price to reach $1.77 in the next year. This suggests a possible upside of 18.2% from the stock's current price. View analysts' price targets for Tocagen.

News headlines about TOCA stock have been trending somewhat positive on Monday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tocagen earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutTocagen.

Tocagen saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,490,000 shares, an increase of 17.3% from the April 30th total of 1,270,000 shares. Based on an average trading volume of 2,200,000 shares, the short-interest ratio is presently 0.7 days. Approximately 8.3% of the company's stock are short sold. View Tocagen's Current Options Chain.

Some companies that are related to Tocagen include IDEAYA Biosciences (IDYA), Cerecor (CERC), Sierra Oncology (SRRA), Evelo Biosciences (EVLO), Harrow Health (HROW), Newron Pharmaceuticals (NWPHF), SUMMIT THERAPEU/S (SMMT), Mustang Bio (MBIO), GlycoMimetics (GLYC), Immunic (IMUX), TapImmune (MRKR), Savara (SVRA), PhaseBio Pharmaceuticals (PHAS), Aldeyra Therapeutics (ALDX) and Checkpoint Therapeutics (CKPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB), Amarin (AMRN), VBI Vaccines (VBIV), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX) and Catalyst Pharmaceuticals (CPRX).

(TOCA) raised $80 million in an initial public offering on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

Tocagen's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.98%), Geode Capital Management LLC (1.63%), State Street Corp (1.47%), Morgan Stanley (1.32%), MYDA Advisors LLC (0.70%) and Deutsche Bank AG (0.23%). Company insiders that own Tocagen stock include Faheem Hasnain, Harry E Gruber, Martin J Duvall and Steven Michael Oliveira. View institutional ownership trends for Tocagen.

TOCA stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, State Street Corp, Parametric Portfolio Associates LLC, Deutsche Bank AG, BlackRock Inc., and UBS Group AG. View insider buying and selling activity for Tocagen.

TOCA stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, MYDA Advisors LLC, Geode Capital Management LLC, and Nuveen Asset Management LLC. Company insiders that have bought Tocagen stock in the last two years include Faheem Hasnain, Harry E Gruber, Martin J Duvall, and Steven Michael Oliveira. View insider buying and selling activity for Tocagen.

Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TOCA stock can currently be purchased for approximately $1.50.

Tocagen has a market capitalization of $35.88 million and generates $40,000.00 in revenue each year. The company earns $-63,520,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Tocagen employs 77 workers across the globe.

The official website for Tocagen is www.tocagen.com.

Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]anceadvisors.com.